 Connection
David Irwin to Hemopexin
This is a "connection" page, showing publications David Irwin has written about Hemopexin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.842 |
|
|
|
-
Lucero MJ, Lisk C, Cendali F, Swindle D, Setua S, Thangaraju K, Pak DI, O'Boyle Q, Lu S, Tolson R, Zaeske S, Rana N, Khan S, Westover N, DavizonCastillo P, George G, Hassell K, Nuss R, Brinkman N, Gentinetta T, Palmer AF, D'Alessandro A, Buehler PW, Irwin DC. Targeting lung heme iron by aerosol hemopexin adminstration in sickle cell disease pulmonary hypertension. Free Radic Biol Med. 2025 Mar 01; 229:458-473.
Score: 0.922
-
Buehler PW, Swindle D, Pak DI, Ferguson SK, Majka SM, Karoor V, Moldovan R, Sintas C, Black J, Gentinetta T, Buzzi RM, Vallelian F, Wassmer A, Edler M, Bain J, Schu D, Hassell K, Nuss R, Schaer DJ, Irwin DC. Hemopexin dosing improves cardiopulmonary dysfunction in murine sickle cell disease. Free Radic Biol Med. 2021 11 01; 175:95-107.
Score: 0.729
-
Yalamanoglu A, Deuel JW, Hunt RC, Baek JH, Hassell K, Redinius K, Irwin DC, Schaer DJ, Buehler PW. Depletion of haptoglobin and hemopexin promote hemoglobin-mediated lipoprotein oxidation in sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2018 11 01; 315(5):L765-L774.
Score: 0.147
-
Yalamanoglu A, Dubach IL, Schulthess N, Ingoglia G, Swindle DC, Humar R, Schaer DJ, Buehler PW, Irwin DC, Vallelian F. Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice. Front Immunol. 2021; 12:627944.
Score: 0.044
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|